查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2058186

支氣管擴張症：新型態療法、未滿足的需求和TPP洞察報告，2026年

Bronchiectasis - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 53 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

支氣管擴張症的新治療方法及對TPP的深入研究

Thelansis 的「支氣管擴張：新興治療方法、未滿足的需求和目標產品概況 (TPP) 洞察報告 - 2026」對該適應症的關鍵新興治療方法和主要藥物發現機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、試驗設計和關鍵意見領袖 (KOL) 的見解。

支氣管擴張概述

支氣管擴張是一種慢性進行性結構性肺部疾病，其特徵是感染疾病、嗜中性白血球氣道發炎和黏液纖毛清除功能障礙的惡性循環所致。這會導致永久性損傷、氣道粘液充盈以及對慢性細菌定植的敏感性增加。其潛在病因多種多樣，包括感染後損傷、囊腫纖維化、原發性纖毛功能障礙、免疫力缺乏低下、過敏性支氣管肺麴菌症、結締組織疾病以及與炎症性腸病相關的氣道疾病；然而，儘管進行了全面的檢查，仍有相當一部分病例病因不明。患者通常表現為慢性咳痰、痰液膿性、肺部症狀反覆加重、呼吸困難和咳血等症狀。高解析度CT掃描若顯示氣道擴張（超過相關血管直徑，即所謂的「印戒徵」）、支氣管壁增厚和「樹枝狀陰影」，即可確診。抗生素的選擇是基於痰液微生物學檢查（鑑定銅綠假單胞菌、流感嗜血桿菌和非結核分枝桿菌）。氣道清除物理治療和祛痰藥（霧化吸入高滲透壓鹽水或甘露醇）仍是治療的基石，同時輔以針對原發疾病的標靶治療。長期吸入性妥布黴素或阿奇黴素可降低綠膿桿菌定植患者的病情加重頻率。支氣管鏡檢查和手術干預用於處理局限性病變和難治性咯血。預後取決於病因和病情加重的頻率，但多學科管理、定期微生物監測、肺部復健和以患者為中心的自我管理教育對於最佳化長期呼吸系統預後至關重要。

透過對醫生和關鍵意見領袖 (KOL) 的調查所獲得的見解：

  • 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更深入的見解，從而進一步豐富了研究成果。
  • 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

  • PowerPoint簡報
  • MS Excel

主要問題

  • 詳細的競爭格局趨勢
  • 管道分析
  • 符合新興治療方法的患者
  • 大公司
  • 主要作用機制
  • 發布日期等的預測
  • 臨床試驗趨勢分析
  • 目標患者群
  • 試驗終點
  • 測試設計
  • 受試者招募標準等。
  • 未滿足的需求和機遇
  • 目前主要治療方法的有效性
  • 未滿足需求的關鍵領域
  • 主要未滿足需求的市場規模估算
  • 目標產品概況
  • 屬性和級別
  • 醫生開立的處方
  • 預期患者佔有率
  • 關鍵KOL洞察對領先新興治療方法的見解
  • 意識
  • 預期用途/處理線
  • 對主要未滿足需求的滿意度
  • KOL評論

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • GlaxoSmithKline
  • AstraZeneca
  • CSL Behring
  • S-INFINITY Pharmaceuticals Co., Ltd
  • Shanghai Huilun Pharmaceutical Co., Ltd.
  • Boehringer Ingelheim
  • Haisco Pharmaceutical Group Co., Ltd.
  • Thirty Respiratory Limited
  • Genentech, Inc.
  • Verona Pharma plc
  • Sanofi
  • Chiesi Farmaceutici SpA
  • Armata Pharmaceuticals, Inc.
  • Renovion, Inc.
  • Insmed Incorporated
  • Reistone Biopharma Company Limited

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
  • 新興治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 領先的新興治療方法—概述和KOL洞察

第3章 產品屬性分析

  • 重點
  • 科學屬性
  • 商業性屬性
  • 產品定位

第4章：一級市場調查

  • 目前治療狀態
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療環境
  • 當前挑戰
  • 未滿足的需求
  • 新興治療方法
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療前景
  • 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

  • 新興治療方法的主要未滿足需求和未來成就
  • TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

簡介目錄

Bronchiectasis Emerging Therapy and TPP Insights

Thelansis's "Bronchiectasis Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Bronchiectasis Overview

Bronchiectasis is a chronic, progressive structural lung disease characterised by irreversible pathological dilatation and destruction of the bronchial walls - resulting from a self-perpetuating cycle of recurrent infection, neutrophilic airway inflammation, and impaired mucociliary clearance - producing permanently damaged, mucus-laden airways susceptible to chronic bacterial colonisation. Underlying aetiologies are diverse, encompassing post-infectious damage, cystic fibrosis, primary ciliary dyskinesia, immunodeficiency states, allergic bronchopulmonary aspergillosis, connective tissue disorders, and inflammatory bowel disease-associated airway disease, with a significant proportion remaining idiopathic despite thorough investigation. Patients present with chronic productive cough, mucopurulent sputum, recurrent pulmonary exacerbations, dyspnoea, and haemoptysis; high-resolution CT demonstrating airway dilatation exceeding accompanying vessel diameter - the signet ring sign - alongside bronchial wall thickening and tree-in-bud opacification establishes diagnosis. Sputum microbiology - identifying Pseudomonas aeruginosa, Haemophilus influenzae, and non-tuberculous mycobacteria - guides antimicrobial selection. Airway clearance physiotherapy and mucoactive agents - hypertonic saline and nebulised mannitol - remain therapeutic cornerstones alongside targeted treatment of underlying aetiology. Inhaled tobramycin or azithromycin-based long-term antibiotic strategies reduce exacerbation frequency in Pseudomonas-colonised patients. Bronchoscopic or surgical intervention addresses localised disease or refractory haemoptysis. Prognosis varies with aetiology and exacerbation burden; multidisciplinary management, regular microbiological surveillance, pulmonary rehabilitation, and patient-centred self-management education are integral to optimising long-term respiratory outcomes.

Insights driven by surveys with physician / key opinion leaders:

  • Survey findings are corroborated and enriched by insights from interviews with leading KOLs
  • Survey is customized based on client requirements

Deliverables format:

  • PowerPoint presentation
  • MS Excel

Key business questions answered:

  • Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
  • Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
  • Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
  • Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
  • KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • GlaxoSmithKline
  • AstraZeneca
  • CSL Behring
  • S-INFINITY Pharmaceuticals Co., Ltd
  • Shanghai Huilun Pharmaceutical Co., Ltd.
  • Boehringer Ingelheim
  • Haisco Pharmaceutical Group Co., Ltd.
  • Thirty Respiratory Limited
  • Genentech, Inc.
  • Verona Pharma plc
  • Sanofi
  • Chiesi Farmaceutici S.p.A.
  • Armata Pharmaceuticals, Inc.
  • Renovion, Inc.
  • Insmed Incorporated
  • Reistone Biopharma Company Limited

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

  • Key takeaways
  • Scientific attributes
  • Commercial attributes
  • Product positioning

4. Primary Market Research

  • Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
  • Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)